According to a news release from Solaris Biotech, the agreement will leverage the firm’s expertise in manufacturing bioreactors, fermenters and filtration systems to help Wildtype create cultivated seafood. The two companies will engage in a collaborative development programme to design a next generation family of bioreactor systems to help meet the growing demand for seafood. The partnership will also see Solaris helping Wildtype further develop and scale its seafood cultivation processes.
Bioreator systems are one of the most important pieces in the productive infrastructure of the cell-cultured seafood business and are pivotal in advancing new cultivated food technologies. As the alternative protein segment grows, bioreactors will play a key role in ensuring the sector meets its full potential.
"Solaris, with our specialised bioprocessing equipment, is uniquely positioned to play a significant role in the advancement of new cultured food technologies," said Matteo Brognoli, managing director of Solaris. "Alternative proteins have become the fastest growing segment for bioreactor systems and we are proud that our cultivators are enabling technology for a leap in the food industry."
"Wildtype is on mission to produce the cleanest, most delicious seafood in the planet," said Justin Kolbeck, Wildtype CEO. "Annual global seafood consumption is expected to go up 23 million tonnes by 2030 and one of the most important pieces in the productive infrastructure are the cultivators we use to grow cells. With Solaris' technologically advanced solutions we have found the right partner to help us scale and make our products more affordable and accessible."